Core Viewpoint - Energy Transfer LP has delivered a total return of over 250% in the last five years, significantly outperforming the S&P 500 [1] Group 1: Financial Performance - The current market capitalization of Energy Transfer is $65 billion, with a current stock price of $19.01 and a dividend yield of 6.97% [1] - The company has shown a gross margin of 12.27% and has experienced a stock price increase of approximately 17% in less than four months [1] Group 2: Growth Potential - To turn a $10,000 investment into $1 million, Energy Transfer would need to achieve a 100x return, requiring a compound annual growth rate (CAGR) of about 16.6% over 30 years [2] - The company expects to increase its distribution by 3% to 5% annually, with a current forward distribution yield exceeding 7% [2] - Energy Transfer has recorded growth in crude oil transportation and natural gas liquids (NGL) fractionation and transportation, with the highest growth in these areas reaching only 6% [3] Group 3: Market Demand - The demand for natural gas is projected to rise, partly due to the increasing construction of data centers, with Energy Transfer having long-term agreements to supply natural gas to data centers operated by Oracle, CloudBurst, and Fermi America [4] Group 4: Investment Viability - While Energy Transfer may not turn a $10,000 investment into $1 million over three decades, it is still considered a viable moneymaker [6] - The company is currently in a strong position, generating ample free cash flow to sustain and grow distributions, and is investing in capital projects to leverage growth opportunities [7]

Core Viewpoint - Recent market volatility has created an opportunity to invest in GigaCloud Technology (GCT), which has shown significant growth as a provider of B2B technology solutions for large parcel merchandise, connecting Asian manufacturers with resellers in the U.S. and Europe [1] Group 1: Revenue Growth - GCT has been recognized on TIME's America's Growth Leaders 2026 list for its impressive compound annual revenue growth rate (CAGR) of approximately 40-45% per year over the past several years [3] - Zacks estimates project GCT's annual revenue to increase by 17% this year and by another 5% in fiscal 2027, reaching $1.6 billion, reflecting a 226% growth over the last five years from $490 million in 2022 [4] Group 2: Earnings Performance - GCT exceeded Q4 EPS expectations, reporting a 37% year-over-year increase to $1.04, surpassing estimates of $0.65 per share by 60% [5] - Full-year fiscal 2025 EPS rose 18% year-over-year to $3.59, significantly up from $0.60 per share in FY22, with positive revenue guidance for Q1 indicating at least 21% growth [8] - Analysts have raised FY26 and FY27 EPS estimates by over 15% in the last 60 days following GCT's Q4 report [9] Group 3: Valuation and Share Buyback - GCT is trading at a forward P/E ratio of 11X, which is a significant discount compared to the S&P 500's 22X and the Zacks Technology Services Industry average of 24X, making it an attractive investment [10] - GCT has committed to returning capital to shareholders through a share buyback program, having executed $33 million in buybacks at an average price of $31.60 per share, representing 30% of its $111 million repurchase plan [12][14] Group 4: Market Momentum - GCT stock has increased by 17% in the last month and has delivered a remarkable return of nearly 700% over the past three years, despite being down 16% from its all-time high of $48 per share [15] - GCT holds a Zacks Rank 1 (Strong Buy) due to positive EPS revision trends and has received an overall "A" Zacks Style Scores grade for Value, Growth, and Momentum [17]

Company Overview - Vertex Pharmaceuticals is a leading company in the biotech sector, particularly known for its dominance in the cystic fibrosis (CF) drug market [5][6]. - The company's market capitalization is approximately $116 billion, with a current stock price of $456.85 [7]. Growth Potential - An initial investment of $100,000 in Vertex could potentially grow to $2 million over 30 years, assuming a compound annual growth rate (CAGR) of 10.5% [4]. - Vertex's key products, Trikafta and Alyftrek, are expected to lose patent exclusivity in 2037 and 2039, respectively, but the company has a strong pipeline of new products to sustain growth [6][8]. Product Pipeline - Vertex is launching new products beyond CF, including Journavx for acute pain and Casgevy, a gene-editing medicine for beta-thalassemia and sickle cell disease, which are expected to contribute to revenue growth [8]. - The company has several late-stage candidates targeting diseases with limited treatment options, such as zimislecel for Type 1 diabetes and inaxaplin for APOL-1-mediated kidney disease [9]. Innovation and Management - Vertex has demonstrated strong innovation capabilities and proactive management strategies to address potential challenges, such as patent expirations and reliance on its CF franchise [10]. - The management's forward-thinking approach positions Vertex as a strong long-term investment opportunity [10]. Investment Strategy - While Vertex is a promising long-term investment, diversification across various industries is recommended, including the addition of exchange-traded funds to track major indexes [11]. - A disciplined and patient investment strategy is essential for achieving significant wealth accumulation by retirement [12].

Core Insights - Southern Copper Corporation (SCCO) reported copper production of 956,270 tons in 2025, reflecting a 1.8% year-over-year decline and falling 1% short of its guidance [1][11] - The company expects weaker ore grades at its Peruvian mines, projecting 2026 copper production at around 911,400 tons, suggesting a 4.7% decline from 2025 levels [1][2] Production and Growth Outlook - Despite near-term challenges, Southern Copper maintains a strong long-term outlook, targeting a significant ramp-up in output to roughly 1.6 million tons by 2035, implying a compound annual growth rate (CAGR) of approximately 5.3% from 2025 levels [2] - To support this growth plan, the company intends to invest nearly $19.9 billion over the next decade, with the majority allocated to projects in Peru [3] - Production is expected to increase to about 1.15 million tons by 2031, surge to roughly 1.476 million tons in 2032, and continue rising steadily to reach the 1.6 million ton target by 2035 [4] Key Projects - Among the key projects, the Tia Maria project in Arequipa, Peru, is expected to start in 2027 with an annual capacity of 120,000 tons of SX-EW copper cathodes [4] - In Mexico, the El Pilar project is expected to start in 2029, contributing around 36,000 tons of copper cathodes annually [4] - The El Arco project in Baja California is projected to come online by 2030, contributing around 190,000 tons of copper [5] - Peru's Los Chancas project is slated to add 130,000 tons of copper starting in 2031, followed by Michiquillay in 2032 with an expected 225,000 tons of copper [5] Market Performance - Southern Copper shares have gained 126.5% in the past year compared to the industry's 102.8% growth [10] - The company is trading at a forward 12-month price/sales multiple of 11.95X, a significant premium to the industry's 5.49X [12]

Core Viewpoint - Morgan Sindall Group reported another "good year," continuing a decade of record profits, with management highlighting sustained growth and strong cash generation despite some softer demand in specific areas [1] Financial Performance - The company achieved a 10% increase in revenue for 2025, reaching just over GBP 5 billion, and a 39% rise in operating profit, resulting in an operating margin of 4.5% [3] - Adjusted profit before tax and amortization (PBTA) rose by 35%, leading to a PBTA margin of 4.6%, while adjusted EPS increased by 33% to 370 pence [3] - Net cash improved by GBP 39 million to GBP 531 million, with a profit-to-cash conversion rate of 87% and operating cash flow of GBP 196 million, which was GBP 60 million higher than the previous year [3] Dividend and Shareholder Returns - The board announced a 20% increase in the full-year dividend to GBP 1.58 per share, with GBP 66 million returned to shareholders during the year [4] - Average daily net cash was GBP 368 million in 2025, with expectations of exceeding GBP 400 million in 2026 as the company pursues partnership opportunities [4] Workload Visibility - The group reported a secured order book and preferred bidder work totaling approximately GBP 19.1 billion, with management suggesting that future revenue visibility could rise to about GBP 30 billion when including certain framework allocations and expected future phases [2] - The emphasis on maintaining a "very strong balance sheet" and significant cash reserves was highlighted as essential for supporting execution and funding organic growth [2]

Group 1 - The core idea is that turning $100,000 into $1 million in a decade requires a CAGR of almost 26%, which is higher than the market's long-term average and even exceeds Vertex Pharmaceuticals' CAGR of 18.2% over the past 10 years [1] - Vertex Pharmaceuticals was much smaller a decade ago and was earlier in its efforts to transform the cystic fibrosis (CF) market, having received FDA approval for Kalydeco in 2012 [2] - The CF franchise will continue to be a growth driver, but the company has a smaller patient population to address now, making it unlikely for the CF business alone to achieve the necessary growth to turn $100,000 into $1 million in the next decade [3] Group 2 - Vertex Pharmaceuticals is looking to its pipeline candidates, inaxaplin and povetacicept, which aim to treat diseases without current medicines, but success will depend on flawless clinical execution and sustained market leadership [4] - There is a precedent in the biopharma industry, as Eli Lilly achieved a CAGR of 29.9% after developing a top-selling drug, but it is uncertain if Vertex can replicate such success [5] - Despite challenges, Vertex Pharmaceuticals remains a buy due to consistent revenue and earnings from its CF products, with new additions like Journavx for acute pain expected to contribute positively [6]

Core Insights - T. Rowe Price Group, Inc. (TROW) reported preliminary assets under management (AUM) of $1.80 trillion as of January 31, 2026, marking a 1.2% increase from the previous month despite net outflows of $5.2 billion, which were partially mitigated by favorable market performance [1][11] AUM Breakdown - As of the end of January, T. Rowe Price's equity products remained at $879 billion, unchanged from December 2025. Fixed income products increased slightly to $213 billion, while multi-asset products rose nearly 3% to $646 billion, indicating strong client demand. Alternative products also saw a 1.7% increase to $59 billion [2][11] - The company's target-date retirement portfolios reached $580 billion, reflecting a 3.4% increase from the prior month, showcasing the strength of its retirement-focused offerings [3] Growth Trends - Over the five-year period from 2020 to 2025, T. Rowe Price's AUM experienced a compound annual growth rate (CAGR) of 3.8%, driven by market appreciation and sustained demand for multi-asset and fixed-income solutions [4] - In terms of long-term performance, 46% of T. Rowe Price's U.S. mutual funds' AUM outperformed the Morningstar median, while 43% exceeded the passive peer median over the five years ending December 31, 2025. Additionally, investment advisory clients outside the United States accounted for 8.8% of total AUM, highlighting geographic diversification [5] Competitive Position - T. Rowe Price benefits from a well-diversified AUM mix across various asset classes, client segments, and geographies, which provides stability to its asset base. The company is well-positioned to sustain AUM growth in the future, supported by a strong brand and consistent investment track record [6] - Peers such as Franklin Resources, Inc. (BEN) and Invesco Ltd. (IVZ) have also shown steady AUM growth, with Franklin reporting a preliminary AUM of $1.71 trillion as of January 31, 2026, up 1.3% sequentially, and Invesco achieving a five-year CAGR of 10% [7][8][9]

Core Insights - Aubrey Capital Management Ltd has completely exited its position in MercadoLibre, selling 5,638 shares for an estimated value of $13.18 million, which was 4.15% of the fund's assets under management [2][9] - As of February 3, 2026, MercadoLibre shares were priced at $2,099.90, reflecting a 10% increase over the past year, although underperforming the S&P 500 by 5.4 percentage points [3][10] - The company's market capitalization stands at $106.46 billion, with a revenue of $26.19 billion and a net income of $2.08 billion for the trailing twelve months [4] Company Overview - MercadoLibre operates a leading e-commerce and fintech platform in Latin America, providing services such as online marketplaces, digital payments (Mercado Pago), credit solutions, logistics, and advertising [6][7] - The company generates revenue through transaction fees, fintech services, advertising, logistics, and value-added services for merchants and consumers [7] - MercadoLibre's logistics network and diversified service offerings provide a competitive advantage in high-growth emerging markets [8] Performance Metrics - The stock has shown strong performance over the years, with a 77% increase since 2023, translating to a compound annual growth rate (CAGR) of 20.9%, compared to the S&P 500's CAGR of 20.4% [10] - Despite recent challenges, including a decline in operating margins from nearly 13% to under 10%, the company continues to grow, with revenue increasing from $22.4 billion to $26.2 billion over the last 12 months [11][12]

Core Viewpoint - Amazon.com Inc. has been a significant success in the stock market, with a stock price prediction for 2030 presenting bullish, bearish, and baseline scenarios based on various growth metrics and market conditions [1]. Group 1: Historical Performance - Amazon's stock has surged over 1,025% from 2014 to 2024, rising from $19.94 to $223.75, with a notable increase of 150.70% from March 2020 to December 2024 [1]. - Revenue increased from $89 billion to $638 billion, a growth of over 616%, while net income grew from $0.241 billion to $59.2 billion, a staggering increase of 24,664.3% [1]. Group 2: Key Drivers of Future Performance - E-commerce: Amazon accounted for 41% of all U.S. e-commerce sales in 2025, despite e-commerce representing only 17% of total retail sales [1]. - Amazon Web Services (AWS): AWS generated $107.6 billion in sales in 2024, remaining the largest cloud provider, although facing competition from Microsoft Azure and Google Cloud [1]. - Advertising: Amazon's advertising revenue reached $56.2 billion in 2024, nearly doubling from the previous three years, and is expected to be a high-margin business line [1]. Group 3: Price Predictions for 2030 - Bull Case: Amazon's stock could reach $431 per share, assuming continued growth in advertising, e-commerce, and AWS, leading to an estimated $150 billion in operating profits [2]. - Bear Case: In a less favorable scenario, the stock could drop to $77 per share due to unsustainable investments and competition, applying a lower P/E ratio of 20x [2]. - Baseline Case: Analysts predict a share price of about $250, with revenue expected to rise from $710 billion in 2025 to $1.153 trillion by 2030, and net income projected to grow from $48.9 billion to $100 billion [2].

Core Insights - The Andersons announced a growth plan targeting a 36% compound annual growth rate (CAGR) in earnings per share (EPS) from $2.56 to $7.00 by 2028 [1] Company Performance - The company has experienced a year-over-year decline in EPS for four consecutive fiscal quarters, including a -26.25% drop in Q3 2025 [7] - The upcoming Q4 earnings report on February 17, 2026, will be crucial in determining if the company is on the right path towards its growth objectives [7] Insider Trading Activity - William E. Krueger, the President and CEO, gifted away 38,200 shares, while Director John T. Stout Jr. executed multiple sales, including a direct open-market sale of 12,500 shares on December 10, 2025, totaling approximately $647,088 [2][5] - Stout's total holdings after his recent transactions amount to 25,940.57 shares, valued at $1.45 million [3] Company Operations - The Andersons Inc. specializes in planting, storing, manufacturing, and merchandising various agricultural products, including grains, ethanol, and plant nutrients [4] - The company is investing $60 million in an ethanol plant to boost capacity by 30 million gallons and is expanding food export terminals to support its growth strategy [6]